Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Summit Therapeu ADR
(NQ:
SMMT
)
24.39
+1.23 (+5.31%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
9,968,749
Open
23.16
Bid (Size)
24.39 (1)
Ask (Size)
24.75 (1)
Prev. Close
23.16
Today's Range
22.96 - 24.95
52wk Range
1.640 - 33.89
Shares Outstanding
97,381,774
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
September 19, 2024
Via
AB Newswire
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
September 19, 2024
Summit Therapeutics' rise could signal emerging opportunities in precision oncology such Nuvectis Pharma (NASDAQ: NVCT), Silexion (NASDAQ:SLXN), and Scorpion leading the charge.
Via
News Direct
Performance
YTD
+823.86%
+823.86%
1 Month
+80.40%
+80.40%
3 Month
+204.88%
+204.88%
6 Month
+643.60%
+643.60%
1 Year
+1204.28%
+1204.28%
More News
Read More
Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?
September 19, 2024
Via
The Motley Fool
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
September 18, 2024
Via
The Motley Fool
Here's How Much $100 Invested In Summit Therapeutics 5 Years Ago Would Be Worth Today
September 13, 2024
Via
Benzinga
Summit Therapeutics Options Trading: A Deep Dive into Market Sentiment
September 11, 2024
Via
Benzinga
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
September 17, 2024
Via
Investor's Business Daily
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
September 17, 2024
Via
Benzinga
Here's Why Everyone's Talking About Summit Therapeutics
September 17, 2024
Via
The Motley Fool
Alphabet To $200? Here Are 10 Top Analyst Forecasts For Monday
September 16, 2024
Via
Benzinga
Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
September 16, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
September 15, 2024
Via
Benzinga
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
September 14, 2024
Via
The Motley Fool
Why Summit Therapeutics Skyrocketed 123% This Week
September 13, 2024
Via
The Motley Fool
Why Summit Therapeutics Stock Is Soaring Again Today
September 12, 2024
Via
The Motley Fool
Signet Jewelers Posts Better-Than-Expected Earnings, Joins NETGEAR, Lovesac And Other Big Stocks Moving Higher On Thursday
September 12, 2024
Via
Benzinga
Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale
September 12, 2024
Via
Investor's Business Daily
Summit Therapeutics Surges on Trial Results: Time to Buy?
September 12, 2024
Via
MarketBeat
Why Summit Therapeutics (SMMT) Stock Is Rising Today
September 12, 2024
Via
Benzinga
Summit Therapeutics Raises $235 Million
September 12, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Is Summit Therapeutics a Buy Now?
September 10, 2024
Via
The Motley Fool
Why Summit Therapeutics Rocketed Over 60% Today
September 09, 2024
Via
The Motley Fool
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
September 09, 2024
Via
Benzinga
Starbucks To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Monday
September 09, 2024
Via
Benzinga
Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda
September 09, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.